OUTCOME-DRIVEN
BIOLOGICS MANUFACTURING
As recombinant protein and monoclonal antibody treatments continue to provide promising pathways for both existing indications and new ones, Resilience has the clinical and commercial experience, expertise, and capacity to be your preferred manufacturing partner.
Our goal is to streamline and accelerate your path to first-in-human studies by more efficiently integrating late discovery activities with early development and to apply our clinical and commercial manufacturing excellence to provide robust and reliable supply for your patients.
